[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Domenge C, Hill C, Lefebvre JL, De Raucourt D, Rhein B, Wibault P, Marandas P, Coche-Dequeant B, Stromboni-Luboinski M, Sancho-Garnier H, Luboinski B, French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC): Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC). Br J Cancer; 2000 Dec;83(12):1594-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC).
  • The objective of the study was to evaluate the effect of neoadjuvant chemotherapy on the survival of patients with oropharyngeal cancer.
  • Patients with a squamous cell carcinoma of the oropharynx for whom curative radiotherapy or surgery was considered feasible were entered in a multicentric randomized trial comparing neoadjuvant chemotherapy followed by loco-regional treatment to the same loco-regional treatment without chemotherapy.
  • The loco-regional treatment consisted either of surgery plus plus radiotherapy or of radiotherapy alone.
  • Three cycles of chemotherapy consisting of Cisplatin (100 mg/m2) on day 1 followed by a 24-hour i.v. infusion of fluorouracil (1000 mg/m2/day) for 5 days were delivered every 21 days.
  • 2-3 weeks after the end of chemotherapy, local treatment was performed.
  • The trial was conducted by the Groupe d'Etude des Tumeurs de la Tête Et du Cou (GETTEC).
  • Overall survival was significantly better (P = 0.03) in the neoadjuvant chemotherapy group than in the control group, with a median survival of 5.1 years versus 3.3 years in the no chemotherapy group.
  • The effect of neoadjuvant chemotherapy on event-free survival was smaller and of borderline significance (P = 0.11).
  • Stratification of the results on the type of local treatment, surgery plus radiotherapy or radiotherapy alone, did not reveal any heterogeneity in the effect of chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Oropharyngeal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Disease-Free Survival. Fatigue / chemically induced. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Leukopenia / chemically induced. Male. Middle Aged. Nausea / chemically induced. Neoadjuvant Therapy. Proportional Hazards Models. Thrombocytopenia / chemically induced. Treatment Outcome. Vomiting / chemically induced

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Control Clin Trials. 1996 Aug;17(4):343-6 [8889347.001]
  • [Cites] Bull Cancer. 1988;75(10):971-8 [3219424.001]
  • [Cites] Cancer. 1985 Mar 1;55(5):1123-8 [4038469.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] Cancer. 1983 Apr 15;51(8):1353-5 [6681726.001]
  • (PMID = 11189100.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] SCOTLAND
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2363468
  •  go-up   go-down


2. Gonzalez-Cuyar LF, Tavora F, Burke AP, Gocke CD, Zimrin A, Sauk JJ, Zhao XF: Monomorphic post-transplant lymphoproliferative disorder of the tongue: case report and review of literature. Diagn Pathol; 2007;2:49

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monomorphic post-transplant lymphoproliferative disorder of the tongue: case report and review of literature.
  • BACKGROUND: Post-transplant lymphoproliferative disorder (PTLD) is a spectrum of hematological diseases arising in context of immunosuppression after organ transplantation.
  • METHODS: Using morphologic and immunophenotypic approaches we have studied a case of monomorphic PTLD of the tongue that developed in a patient following unilateral kidney and pancreas transplantation on immunosuppressive therapy.
  • RESULTS: The neoplasm showed large cell morphology and B-cell phenotype.
  • Complete remission was obtained after decreasing immunosuppressive therapy.
  • CONCLUSION: This rare case increased our awareness of PTLD in the oral cavity of patients following solid organ transplantation and immunosuppressive therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Med. 2005;56:29-44 [15660500.001]
  • [Cites] Hematol Oncol Clin North Am. 1993 Apr;7(2):431-45 [8468275.001]
  • [Cites] J Heart Lung Transplant. 2005 Jun;24(6):671-9 [15949726.001]
  • [Cites] Nephrology (Carlton). 2006 Aug;11(4):355-66 [16889577.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Oct;102(4):e24-8 [16997090.001]
  • [Cites] Am J Hematol. 2007 Mar;82(3):208-14 [17022049.001]
  • [Cites] Curr Drug Targets. 2007 Apr;8(4):533-41 [17430124.001]
  • [Cites] Transplant Proc. 1991 Feb;23(1 Pt 2):1101-3 [1899153.001]
  • [Cites] Mod Pathol. 1989 Nov;2(6):583-92 [2587566.001]
  • [Cites] Lancet. 1967 Jun 3;1(7501):1171-4 [4165129.001]
  • [Cites] Pediatr Transplant. 1999 Nov;3(4):271-81 [10562971.001]
  • [Cites] Transplantation. 1999 Nov 27;68(10):1517-25 [10589949.001]
  • [Cites] Transplantation. 2001 Apr 27;71(8):1076-88 [11374406.001]
  • [Cites] Laryngoscope. 2001 Jun;111(6):997-1001 [11404611.001]
  • [Cites] Pediatr Transplant. 2001 Jun;5(3):198-203 [11422823.001]
  • [Cites] Hum Pathol. 2001 Nov;32(11):1264-8 [11727268.001]
  • [Cites] Leuk Lymphoma. 2003 May;44(5):875-8 [12802929.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2003 Jul-Aug;65(4):226-9 [14564099.001]
  • [Cites] Oral Oncol. 2004 Jan;40(1):103-6 [14662423.001]
  • [Cites] Hum Pathol. 2004 May;35(5):632-5 [15138941.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2004 Apr;12(2):122-6 [15167049.001]
  • [Cites] J Clin Periodontol. 2004 Jul;31(7):581-5 [15191596.001]
  • [Cites] Clin Infect Dis. 2004 Oct 1;39(7):1016-23 [15472855.001]
  • [Cites] N Engl J Med. 1967 Jul 27;277(4):163-70 [4166031.001]
  • [Cites] Br Med J. 1968 Dec 21;4(5633):746-8 [4881420.001]
  • [Cites] Transplant Proc. 1969 Mar;1(1):106-12 [4944206.001]
  • [Cites] Lancet. 1984 Mar 17;1(8377):583-7 [6142304.001]
  • [Cites] Eur J Haematol. 2005 Mar;74(3):267-70 [15693799.001]
  • (PMID = 18093326.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2231341
  •  go-up   go-down


3. Lopes da Silva R, Fernandes T, Lopes A, Santos S, Mafra M, Rodrigues AS, de Sousa AB: B lymphoblastic lymphoma presenting as a tumor of the nasopharynx in an adult patient. Head Neck Pathol; 2010 Dec;4(4):318-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In adults, non-Hodgkin's lymphoma (NHL) is the second most common neoplasm found in the head and neck region after squamous cell carcinoma.
  • We report the case of a 28-year-old male diagnosed with a B lymphoblastic lymphoma (CD20-; CD79a+; CD3-; CD10+; PAX5+, CyclinD1-; TdT+) of the nasopharynx extending to the deep and superficial structures of the right hemiface, to the skull base with an intracranial component and a small but detectable bone marrow involvement, who was started on chemotherapy with a complete response.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adult. Biopsy. Humans. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology. Male. Remission Induction

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rinsho Ketsueki. 1999 Nov;40(11):1193-7 [10624131.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] Am J Surg Pathol. 2000 Nov;24(11):1480-90 [11075849.001]
  • [Cites] Am J Clin Pathol. 2001 Jun;115(6):868-75 [11392884.001]
  • [Cites] Head Neck. 2001 Jul;23(7):547-58 [11400243.001]
  • [Cites] Leuk Lymphoma. 2001 Sep-Oct;42(5):1005-13 [11697617.001]
  • [Cites] Chin Med J (Engl). 2000 Feb;113(2):148-50 [11775540.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2220-4 [14576732.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1624-30 [15178574.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2004 Jul;26(7):425-9 [15355649.001]
  • [Cites] Am J Clin Pathol. 1983 Mar;79(3):387-91 [6338702.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):768-76 [4016670.001]
  • [Cites] Laryngoscope. 1987 Mar;97(3 Pt 1):291-300 [3821348.001]
  • [Cites] Am J Surg Pathol. 1987 Jun;11(6):418-29 [3496014.001]
  • [Cites] AJR Am J Roentgenol. 1987 Oct;149(4):785-91 [3498332.001]
  • [Cites] J Clin Oncol. 1989 Sep;7(9):1275-80 [2769328.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1190-7 [2205355.001]
  • [Cites] Strahlenther Onkol. 1996 Jul;172(7):356-66; discussion 367-8 [8693402.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 Jan;32B(1):19-23 [8729614.001]
  • [Cites] Leuk Lymphoma. 1996 Nov;23(5-6):577-82 [9031089.001]
  • [Cites] No Shinkei Geka. 2005 Nov;33(11):1107-11 [16277225.001]
  • [Cites] J Egypt Natl Canc Inst. 2005 Mar;17(1):15-9 [16353078.001]
  • [Cites] J Cutan Pathol. 2006 Sep;33(9):649-53 [16965342.001]
  • [Cites] Leuk Lymphoma. 2006 Oct;47(10):2132-9 [17071487.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jun;103(6):814-9 [17531941.001]
  • [Cites] Ann Hematol. 2008 Aug;87(8):677-9 [18365194.001]
  • [Cites] Arch Dermatol. 2008 Sep;144(9):1155-62 [18794461.001]
  • [Cites] Ann Hematol. 2009 May;88(5):441-7 [18931844.001]
  • (PMID = 20730608.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2996508
  •  go-up   go-down


Advertisement
4. Grogg KL, Jung S, Erickson LA, McClure RF, Dogan A: Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma: a clonal T-cell lymphoproliferative disorder with indolent behavior. Mod Pathol; 2008 Jun;21(6):708-15
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma: a clonal T-cell lymphoproliferative disorder with indolent behavior.
  • Fourteen represented solitary lesions on the head/neck (n=9), upper extremity (n=4), or trunk (n=1).
  • The majority resolved without relapse, one without treatment, four with excision, and four with radiation therapy.
  • One patient developed local recurrence.
  • The patient with multiple lesions had disease progression despite chemotherapy and stem cell transplant.
  • Diagnosis requires molecular genetic analysis, as prominent cytologic atypia and immunophenotypic aberrancy are rare.
  • The differential diagnosis includes reactive lymphoid hyperplasia, mycosis fungoides and cutaneous B-cell lymphomas.
  • In patients with isolated cutaneous lesions, the indolent behavior of this rare T-cell neoplasm should be recognized to avoid unnecessary treatment.
  • [MeSH-major] CD4-Positive T-Lymphocytes / pathology. Lymphoma, T-Cell, Cutaneous / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. History, 17th Century. Humans. Immunohistochemistry. Lymphoma, B-Cell / pathology. Male. Middle Aged. Mycosis Fungoides / pathology. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18311111.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Shah JP, Gil Z: Current concepts in management of oral cancer--surgery. Oral Oncol; 2009 Apr-May;45(4-5):394-401
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Surgery is the most well established mode of initial definitive treatment for a majority of oral cancers.
  • The factors that affect choice of treatment are related to the tumor and the patient.
  • The radial forearm free flap provides excellent soft tissue and lining for soft tissue defects in the oral cavity.
  • Over the course of the past thirty years there has been improvement in the overall survival of patients with oral carcinoma largely due to the improved understanding of the biology of local progression, early identification and treatment of metastatic lymph nodes in the neck, and employment of adjuvant post-operative radiotherapy or chemoradiotherapy.
  • The role of surgery in primary squamous cell carcinomas in other sites in the head and neck has evolved with integration of multidisciplinary treatment approaches employing chemotherapy and radiotherapy either sequentially or concurrently.
  • Surgery thus remains the mainstay of management of a majority of neoplasms arising in the head and neck area.
  • Similarly, the role of the surgeon is essential throughout the life history of a patient with a malignant neoplasm in the head and neck area, from initial diagnosis through definitive treatment, post-treatment surveillance, management of complications, rehabilitation of the sequelae of treatment, and finally for palliation of symptoms.
  • [MeSH-major] Mouth Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Protocols. Bone Neoplasms / surgery. Combined Modality Therapy. Head and Neck Neoplasms / surgery. Humans. Patient Selection. Reconstructive Surgical Procedures. Skin Neoplasms / surgery. Skull Base Neoplasms / surgery. Soft Tissue Neoplasms / surgery. Surgical Flaps. Treatment Outcome


6. Khademi B, Mahmoodi J, Omidvari S, Mohammadianpanah M: Treatment results of nasopharyngeal carcinoma: a 15-year single institutional experience. J Egypt Natl Canc Inst; 2006 Jun;18(2):147-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results of nasopharyngeal carcinoma: a 15-year single institutional experience.
  • BACKGROUND: Nasopharyngeal Carcinoma (NPC) is a common malignant neoplasm of the head and neck that occurs most commonly in people in the South Eastern Asia but its condition in Iran is not much clear.
  • OBJECTIVE: In this retrospective study, we evaluated the treatment characteristics determining the outcome in patients with NPC.
  • PATIENTS AND METHODS: In this retrospective study, we reviewed the records of one hundred and seven patients with biopsy proven diagnosis of NPC who were referred to the radiation oncology department, Nemazee Hospital, Shiraz University of Medical Sciences, Iran, during the time period from January 1985 to December 2000.
  • Sixty-two patients (57.5%) received radiotherapy combined with adjuvant chemotherapy which consisted of cisplatin and 5-fluorouracil.
  • Eighty-six patients (80.4%) had WHO II-III histopathologic diagnosis.
  • The patients who received more than 60Gy radiation had a better prognosis (p=0.02), however; sequential adjuvant chemotherapy had no impact on survival and response (p=0.6).
  • This study failed to demonstrate improvement in the outcome regarding overall and disease-free survival by adding sequential adjuvant chemotherapy after radiotherapy for patients with advanced NPC.
  • [MeSH-major] Nasopharyngeal Neoplasms / mortality. Nasopharyngeal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17496940.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


7. Cranmer LD, Engelhardt C, Morgan SS: Treatment of unresectable and metastatic cutaneous squamous cell carcinoma. Oncologist; 2010;15(12):1320-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of unresectable and metastatic cutaneous squamous cell carcinoma.
  • Cutaneous squamous cell carcinoma (SCC) is an already common disorder with a rapidly increasing incidence.
  • Treatment of early disease depends primarily on surgery or destructive techniques.
  • In contrast to the frequency of early SCC, unresectable or metastatic SCC is relatively rare, but potentially life-threatening without clearly proven treatment options.
  • Few rigorous studies of the treatment of advanced SCC have been undertaken.
  • In the past, various agents have been explored in a limited fashion, including chemotherapy (cisplatin, fluoropyrimidines, bleomycin, doxorubicin), 13-cis-retinoic acid, and interferon-α2a.
  • Clinical activity has been suggested by these trials, but their small sizes, heterogeneous patient populations, and lack of randomization have hindered the use of their results in defining treatment paradigms.
  • This treatment did not improve time to recurrence or prevent secondary cutaneous SCC from developing.
  • Only the conduct of rigorous trials, with well-defined endpoints, adequate patient numbers, and preferably randomization, can prove the clinical efficacy of this promising treatment approach and define better therapy for this vexing clinical problem.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Neoplasm Recurrence, Local / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Clinical Trials as Topic. Humans. Neoplasm Staging. Practice Guidelines as Topic. Survival Rate. Treatment Outcome


8. Boguszewska D, Mazurkiewicz M, Grzybowska-Szatkowska L: [Induction chemotherapy and radiotherapy in locally advanced head and neck carcinoma]. Otolaryngol Pol; 2000;54 Suppl 31:18-20
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Induction chemotherapy and radiotherapy in locally advanced head and neck carcinoma].
  • The value of inductive chemotherapy preceding the radical irradiation of locally advanced neoplasms of head and neck has been estimated.
  • A reaction to treatment in the form of CR and PR has been achieved in 71.5% of the treated patients.
  • Irradiation was started in two to four weeks after chemotherapy had been stopped.
  • After combined treatment the proportion of 69.5% CR and PR was achieved.
  • The average length of time of CR and PR was 8.7 months.
  • Treatment was well tolerated.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10974833.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] POLAND
  •  go-up   go-down


9. Duvillard C, Polycarpe E, Romanet P, Chauffert B: [Intratumoral chemotherapy: experimental data and applications to head and neck tumors]. Ann Otolaryngol Chir Cervicofac; 2007 Jun;124(2):53-60
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intratumoral chemotherapy: experimental data and applications to head and neck tumors].
  • [Transliterated title] La chimiothérapie intratumorale: aspects expérimentaux et applications aux tumeurs de la tête et du cou.
  • OBJECTIVE: Intratumoral chemotherapy consists in the direct intratumoral injection of the anticancer drugs.
  • MATERIAL AND METHODS: This work reviews and analyses the national and international literature about experimental and clinical studies of intratumoral chemotherapy.
  • RESULTS: Numerous experimental studies validated its theoretical advantages compared with the intravenous one: drug intratumoral concentration increase, antitumoral activity improvement and systemic toxicity decrease.
  • But they also underlined its limits: the high clearance and the non-homogeneous drug diffusion.
  • Research works led to the improvement of the results and performed clinical trials with slow release devices (microspheres, collagen matrix with or without vasoconstrictive agent), anticancer drug in an aqueous solution with a vasoconstrictive agent, intratumoral injection in association with electrochemotherapy or radiotherapy.
  • CONCLUSIONS: Intratumoral chemotherapy is an effective therapeutic even when used after the classical treatments.
  • Improvements are necessary to define the best drugs, injection technique, treatment periodicity and indications.
  • Intratumoral chemotherapy deserves better interest at the moment where drugs and antibodies limit their action to the cancer cells preserving the healthy ones.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Drug Administration Routes. Electric Stimulation / methods. Feasibility Studies. Female. Humans. Injections. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17434136.001).
  • [ISSN] 0003-438X
  • [Journal-full-title] Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris
  • [ISO-abbreviation] Ann Otolaryngol Chir Cervicofac
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 38
  •  go-up   go-down


10. Janot F, de Raucourt D, Benhamou E, Ferron C, Dolivet G, Bensadoun RJ, Hamoir M, Géry B, Julieron M, Castaing M, Bardet E, Grégoire V, Bourhis J: Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol; 2008 Dec 1;26(34):5518-23
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma.
  • PURPOSE: Full-dose reirradiation combined with chemotherapy has been shown to be feasible after salvage surgery with acceptable toxicity.
  • The Groupe d'Etude des Tumeurs de la Tête et du Cou and Groupe d'Oncologie Radiothérapie Tête Et Cou groups performed a randomized study to assess its efficacy.
  • PATIENTS AND METHODS: Between 1999 and 2005, 130 patients with head and neck cancer were treated with salvage surgery and randomly assigned to full-dose reirradiation combined with chemotherapy (RT arm) or to observation (a "wait and see" approach; WS arm).
  • Patients in the RT arm received 60 Gy over 11 weeks combined with concomitant fluorouracil and hydroxyurea.
  • At 2 years, 39% of patients in the RT arm and 10% in the WS arm experienced grade 3 or 4 late toxicity according to Radiation Therapy Oncology Group criteria (P = .06).
  • CONCLUSION: Full-dose reirradiation combined with chemotherapy after salvage surgery significantly improved DFS, but had no significant impact on OS.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Head and Neck Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Disease Progression. Female. Fluorouracil / pharmacology. Humans. Hydroxyurea / pharmacology. Male. Neoplasm Metastasis. Postoperative Period. Recurrence. Salvage Therapy. Treatment Outcome


11. Tapia-Perez H, Sanchez-Aguilar M, Torres-Corzo JG, Rodriguez-Leyva I, Gonzalez-Aguirre D, Gordillo-Moscoso A, Chalita-Williams C: Use of statins for the treatment of spontaneous intracerebral hemorrhage: results of a pilot study. Cent Eur Neurosurg; 2009 Feb;70(1):15-20
Hazardous Substances Data Bank. ROSUVASTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of statins for the treatment of spontaneous intracerebral hemorrhage: results of a pilot study.
  • BACKGROUND AND STUDY AIMS: Spontaneous intracerebral hemorrhage (ICH) represents the most fatal kind of stroke, and there is still no treatment available that improves the outcome.
  • Exclusion criteria were a history of neoplasm, head injury four weeks before admission, non-hypertensive reasons, brainstem hemorrhage, steroid administration, cranial surgery, initial hydrocephalus, and NIHSS > or =30.
  • Further clinical trials are necessary to confirm a possible therapeutic effect and evaluate the toxicity of statins.
  • [MeSH-major] Cerebral Hemorrhage / drug therapy. Fluorobenzenes / therapeutic use. Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use. Pyrimidines / therapeutic use. Sulfonamides / therapeutic use
  • [MeSH-minor] Adult. Aged. Antihypertensive Agents / therapeutic use. Female. Glasgow Coma Scale. Hospital Mortality. Humans. Male. Middle Aged. Odds Ratio. Pilot Projects. Proportional Hazards Models. Prospective Studies. Retrospective Studies. Rosuvastatin Calcium. Sample Size. Stroke / drug therapy. Stroke / mortality. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Statins.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19197830.001).
  • [ISSN] 1868-4904
  • [Journal-full-title] Central European neurosurgery
  • [ISO-abbreviation] Cent Eur Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antihypertensive Agents; 0 / Fluorobenzenes; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Pyrimidines; 0 / Sulfonamides; 83MVU38M7Q / Rosuvastatin Calcium
  •  go-up   go-down


12. Wreesmann VB, Estilo C, Eisele DW, Singh B, Wang SJ: Downregulation of Fanconi anemia genes in sporadic head and neck squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec; 2007;69(4):218-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Downregulation of Fanconi anemia genes in sporadic head and neck squamous cell carcinoma.
  • Fanconi anemia (FA) is an autosomal recessive disorder characterized by cellular hypersensitivity to DNA crosslinking agents, progressive bone marrow failure, and cancer predisposition to solid malignancies, especially head and neck squamous cell carcinoma (HNSCC).
  • Since FA pathway-deficient cells are hypersensitive to DNA crosslinking chemotherapy agents, the presence of somatic FA gene inactivation in sporadic cancers may be of clinical interest.
  • METHODS: The expression of the FA genes FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCJ, FANCL and FANCM in 11 HNSCC cell lines and 49 tongue carcinoma samples was studied with quantitative real-time polymerase chain reaction.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Down-Regulation / physiology. Fanconi Anemia / genetics. Gene Expression / genetics. Tongue Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. DNA Primers / genetics. DNA, Complementary / genetics. Female. Humans. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. RNA / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Fanconi Anemia.
  • Genetic Alliance. consumer health - Anemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 S. Karger AG, Basel
  • (PMID = 17409780.001).
  • [ISSN] 0301-1569
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Complementary; 63231-63-0 / RNA
  •  go-up   go-down


13. Sautois B, Martin M, Demez P, Piret P, Devillers D, Moreau P: [Monoclonal antibodies for the treatment of head and neck cancer]. Rev Med Liege; 2009 May-Jun;64(5-6):284-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Monoclonal antibodies for the treatment of head and neck cancer].
  • [Transliterated title] Place des anticorps monoclonaux dans le traitement des tumeurs de la tête et du cou.
  • Monoclonal antibodies are now part of the armamentarium available for the treatment of head and neck cancer.
  • Cétuximab, a monoclonal antibody targeting EGFR, improves overall survival as compared with radiotherapy alone as radical treatment of locally advanced head and neck cancer.
  • In the metastatic setting adding cétuximab to platinum based chemotherapy improves overall survival as compared with chemotherapy alone, a first-time event over a 30-year period, unfortunately not yet accessible to the Belgian patients.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Head and Neck Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19642460.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab
  •  go-up   go-down


14. Granados-Garcia M, Luna-Ortiz K, Castillo-Oliva HA, Villavicencio-Valencia V, Herrera-Gómez A, Mosqueda-Taylor A, Aguilar-Ponce JL, Poitevin-Chacón A: Free osseous and soft tissue surgical margins as prognostic factors in mandibular osteosarcoma. Oral Oncol; 2006 Feb;42(2):172-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Free osseous and soft tissue surgical margins as prognostic factors in mandibular osteosarcoma.
  • Osteosarcoma is an infrequent, locally aggressive neoplasm in the head and neck region.
  • To date, surgery is the mainstay of treatment.
  • However, patients with mandibular osteosarcomas usually have a locally advanced disease at diagnosis and therefore represent a therapeutic challenge because surgical margins are difficult to obtain due to aesthetic and functional concerns.
  • To evaluate possible prognostic factors implicated in recurrence, persistence or relapse in osteosarcoma of the mandible, with special reference to the soft tissue and bone surgical margins.
  • A series of 20 patients with mandibular osteosarcomas treated at the Instituto Nacional de Cancerología (México) from 1985 to 1999 are reviewed.
  • Twelve cases were treated with surgery alone, 3 patients with surgery and adjuvant radiotherapy, 1 had neoadjuvant chemotherapy followed by surgery, 1 had neoadjuvant chemotherapy, surgery and postoperative radiotherapy, 1 with surgery and adjuvant chemotherapy, 1 with surgery followed by adjuvant chemotherapy and radiotherapy and one patient rejected treatment.
  • Between 1985 and 1992 these neoplasms were treated by means of total mandibulectomy, independently of tumor size, but between 1993 and 1999 the policy was to practice smaller resections but long enough to obtain macroscopic surgical free margins.
  • There was not significant difference between both periods in terms of tumor size (6.0 cm vs. 6.02 cm at the time of surgery) nor in local control and survival.
  • Soft tissue involvement as reported by histological study was strongly associated with recurrence (p = 0.0024).
  • Extent of margins in soft tissue is the limiting factor for local control.
  • [MeSH-major] Mandibular Neoplasms / surgery. Osteosarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Prognosis. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16246617.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Cannizzaro MA, Cavallaro A, Veroux M, Costanzo M, Ferraù F, Veroux P: [A case of pleomorphic liposarcoma involving a parahypopharyngeal site]. Chir Ital; 2003 May-Jun;55(3):451-6
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Soft tissue sarcomas are uncommon, accounting for fewer than 1% of malignant neoplasms of the head and neck.
  • We report the case of a 20-year-old man with a malignant hypopharyngeal pleomorphic liposarcoma, successfully treated with surgery and adjuvant radio- and chemotherapy.
  • [MeSH-major] Hypopharyngeal Neoplasms / therapy. Liposarcoma / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12872584.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


16. Kartha SS, Bumpous JM: Synovial cell sarcoma: diagnosis, treatment, and outcomes. Laryngoscope; 2002 Nov;112(11):1979-82
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synovial cell sarcoma: diagnosis, treatment, and outcomes.
  • Three percent of cases arise in the head and neck region.
  • It is thought that head and neck synovial sarcoma has a better prognosis than tumors of the extremities.
  • Our experience has demonstrated aggressive behavior of this neoplasm in the head and neck.
  • METHODS: We obtained the records of patients diagnosed with head and neck synovial sarcoma from the Tumor Registry of the University of Louisville School of Medicine (Louisville, KY) and affiliated hospitals for data compiled between January 1990 and December 2000.
  • Data on patient demographics, clinical findings and symptoms, histological findings, treatment, extent of disease, recurrence, and survival were recorded.
  • All patients received chemotherapy after recurrence.
  • Four of the five patients had local recurrence, and all five of the patients developed distant metastases.
  • CONCLUSIONS: Synovial cell sarcoma of the head and neck is a disease of young people and carries a poor prognosis.
  • The aggressive nature of the disease may require modification of accepted treatment modalities and sequence.
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / therapy. Sarcoma, Synovial / diagnosis. Sarcoma, Synovial / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Male. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12439166.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Pigneret S, Baudon Lecame M, Chédru Legros V, Choussy O, Babin E: [Acute mesenteric ischemia and rhinopharyngeal carcinoma]. Rev Laryngol Otol Rhinol (Bord); 2007;128(1-2):105-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To determine the links between radiation therapy, chemotherapy, nasopharyngeal carcinoma and mesenteric ischemia.
  • MATERIAL AND METHODS: A case of 69 year old man with a nasopharyngeal carcinoma, treated by radiation therapy and chemotherapy, who developed a lethal mesenteric ischemia is described.
  • A review of literature had been made on Pubmed with terms: "Mesenteric ischemia" and cisplatin, 5-FU or fluorouracil, radiation therapy, cancer or neoplasm, "head and neck cancer" or "carcinoma of the nasopharynx.
  • Chimiotherapy with 5-fluorouracile and cisplatine, radiation therapy and morphine were suspected.
  • According to literature, responsibility of morphine and radiation therapy is uncertain.
  • CONCLUSION: Mesenteric ischemia is an uncommon adverse effect of a treatment with cisplatin and 5-FU.
  • It's the second case of mesenteric ischemia associated with a treatment with 5-FU and cisplatin in a patient with a nasopharyngeal carcinoma.
  • [MeSH-major] Carcinoma / pathology. Carcinoma / therapy. Ischemia / etiology. Ischemia / pathology. Mesentery / blood supply. Mesentery / pathology. Nasopharyngeal Neoplasms / pathology. Nasopharyngeal Neoplasms / therapy
  • [MeSH-minor] Acute Disease. Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Combined Modality Therapy. Fatal Outcome. Humans. Male. Radiotherapy / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633679.001).
  • [ISSN] 0035-1334
  • [Journal-full-title] Revue de laryngologie - otologie - rhinologie
  • [ISO-abbreviation] Rev Laryngol Otol Rhinol (Bord)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


18. Gierek T, Smółka W, Paluch J: [Chondrosarcomas of the larynx and sinus maxillaris--review of literature and report of three cases]. Otolaryngol Pol; 2009 May-Jun;63(3):279-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chondrosarcoma is a very rare neoplasm in the head and neck region.
  • The most reasonable treatment is radical surgery.
  • Radiotherapy and chemotherapy are of little value.
  • [MeSH-major] Chondrosarcoma / pathology. Chondrosarcoma / therapy. Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / therapy. Maxillary Sinus Neoplasms / pathology. Maxillary Sinus Neoplasms / therapy
  • [MeSH-minor] Adult. Aged, 80 and over. Combined Modality Therapy. Disease Progression. Female. Humans. Male. Middle Aged. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19886537.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 24
  •  go-up   go-down


19. Focan C, Focan-Henrard D, Kreutz F, Moeneclaey N: [Chronobiological considerations for the management of human head and neck cancer]. Pathol Biol (Paris); 2003 Jun;51(4):201-3
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chronobiological considerations for the management of human head and neck cancer].
  • [Transliterated title] Considérations chronobiologiques pour la prise en charge des tumeurs de la tête et du cou chez l'homme.
  • The authors reviewed experimental and clinical data (ie, cell kinetics and its circadian control by cyclins, circadian expression of clock genes, chronotolerance to anticancer agents.) justifying to consider the temporal dimension in the medical treatment of human head and neck cancer.
  • Excellent tolerance and interesting tumour outcome allowed to conclude to an optimised therapeutic index.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chronotherapy. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Case Management. Circadian Rhythm. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12852988.001).
  • [ISSN] 0369-8114
  • [Journal-full-title] Pathologie-biologie
  • [ISO-abbreviation] Pathol. Biol.
  • [Language] fre
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


20. Amiri-Kordestani L, Priebat D, Chia SH: Follicular dendritic cell sarcoma of the neck: case report and review of current diagnostic and management strategies. Ear Nose Throat J; 2010 Jul;89(7):E14-7
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Follicular dendritic cell sarcoma (FDCS) is a rare malignant neoplasm that can clinically mimic a number of other tumors.
  • Radiation therapy and/or chemotherapy may be considered for incompletely resected tumors and for tumors with poor prognostic features, but the exact role of adjuvant therapy is unknown.
  • We report a case of cervical FDCS in a 39-year-old black man, and we review the presentation and management of this disorder, with emphasis on the differential diagnosis.
  • [MeSH-major] Dendritic Cell Sarcoma, Follicular / radiography. Dendritic Cell Sarcoma, Follicular / surgery. Head and Neck Neoplasms / radiography. Head and Neck Neoplasms / surgery
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20628972.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Leach BC, Kulbersh JS, Day TA, Cook J: Cranial neuropathy as a presenting sign of recurrent aggressive skin cancer. Dermatol Surg; 2008 Apr;34(4):483-97
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The purpose of this study was to identify and characterize recurrent skin cancers of the head and neck presenting with cranial neuropathies and to review the presentation and the management for this rare subset of cutaneous neoplasms.
  • MATERIALS AND METHODS: A retrospective review was performed for all patients with previous related cutaneous neoplasms presenting with cranial neuropathies referred to a single academic tertiary-care head and neck tumor program from 1999 to 2007.
  • Six cases of head and neck carcinoma with demonstrable cranial neuropathy were identified and analyzed by clinical history, radiographic and surgical findings, and treatment and survival data.
  • Symptoms were present for an average of 7 months prior to diagnosis of perineural recurrence.
  • Treatment consisted of various combinations of surgery, radiation, and chemotherapy for five patients, and one patient declined any intervention.
  • CONCLUSION: Cranial neuropathy is a rare presentation of recurrent cutaneous neoplasms of the head and neck.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Cranial Nerve Diseases / etiology. Head and Neck Neoplasms / pathology. Melanoma / pathology. Neoplasm Recurrence, Local / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Cohort Studies. Humans. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18248467.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Robertson GS, Crocker SJ, Nicholson DW, Schulz JB: Neuroprotection by the inhibition of apoptosis. Brain Pathol; 2000 Apr;10(2):283-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Consistent with the proposal that apoptosis plays a central in role human neurodegenerative disease, caspase-3 activation has recently been observed in stroke, spinal cord trauma, head injury and Alzheimer's disease.
  • Indeed, peptide-based caspase inhibitors prevent neuronal loss in animal models of head injury and stroke suggesting that these compounds may be the forerunners of non-peptide small molecules that halt apoptosis processes implicated in these neurodegenerative disorders.
  • A clear link between an hereditary neurodegenerative disorder and failed caspase inhibition has recently been proposed for spinal muscular atrophy (SMA).
  • Taken together, these findings suggest that anti-apoptotic strategies may some day have utility in the treatment of neurodegenerative disease.
  • The present review will summarize some of the recent evidence suggesting that apoptosis inhibitors may become a practical therapeutic approach for both acute and chronic neurodegenerative conditions.
  • [MeSH-major] Apoptosis / drug effects. Neuroprotective Agents / pharmacology
  • [MeSH-minor] Animals. Brain Ischemia / enzymology. Brain Ischemia / physiopathology. Caspase 3. Caspases / chemistry. Caspases / metabolism. Enzyme Activation / physiology. Humans. Multigene Family / physiology. Neoplasm Proteins / genetics. Neoplasm Proteins / pharmacology. Neurodegenerative Diseases / drug therapy

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10764048.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] SWITZERLAND
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Neuroprotective Agents; 0 / immunosuppressive acidic protein; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  • [Number-of-references] 63
  •  go-up   go-down


23. Betz CS, Jäger HR, Brookes JA, Richards R, Leunig A, Hopper C: Interstitial photodynamic therapy for a symptom-targeted treatment of complex vascular malformations in the head and neck region. Lasers Surg Med; 2007 Aug;39(7):571-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interstitial photodynamic therapy for a symptom-targeted treatment of complex vascular malformations in the head and neck region.
  • BACKGROUND AND OBJECTIVES: Photodynamic therapy is based on an interaction of a drug and light in oxygenated tissue.
  • The photosensitizing drug Foscan is licensed in the EU for the treatment of advanced head and neck cancer.
  • The light can be applied by surface illumination or directly into tumour tissue by optical fibres.
  • This raises the possibility of using this therapy in the treatment of benign neoplasms in the head and neck.
  • The treatments were carried out using Temoporphin (Foscan) 0.15 mg/kg; the drug-light-interval was 4 days.
  • Multiple fibres were positioned either image guided [13] or clinically [12] to ensure accurate targeting of tissue while avoiding damage of the surrounding and overlying tissue.
  • RESULTS: In all cases there was a significant reduction in the volume of abnormal tissue without damage to the overlying skin; the results were objectified using MRI-imaging, CT-volumetry and surface optical scanning.
  • Post-treatment pain and swelling were successfully controlled with steroids and a variety of analgesics (opioids and non-steroidal anti-inflammatories).
  • The treatment is safe, effective and repeatable and merits further evaluation.
  • [MeSH-major] Mesoporphyrins / therapeutic use. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use. Vascular Malformations / drug therapy
  • [MeSH-minor] Adult. Diagnosis, Differential. Follow-Up Studies. Head. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neck. Retrospective Studies. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Vascular Malformations.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17868106.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mesoporphyrins; 0 / Photosensitizing Agents; FU21S769PF / temoporfin
  •  go-up   go-down


24. Cabanillas F: Front-line management of diffuse large B cell lymphoma. Curr Opin Oncol; 2010 Nov;22(6):642-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With modern treatment regimens, approximately 75% of patients with this disorder can be cured in contrast with 40% in the past.
  • SUMMARY: Areas of consensus include: use of rituximab with CHOP as part of front-line treatment, lack of effectiveness of maintenance rituximab in contrast to follicular low-grade lymphomas is also acknowledged, and dose-dense R-CHOP-14 regimen has not been compared head to head with R-CHOP-21.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Neoplasm Staging. Prednisone / administration & dosage. Rituximab. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20811278.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


25. Rodarte CM, Abdallah OA, Barbosa NF, Koch Lde O, Resende UM: [Cutaneous reactions due to the use of epidermal growth factor receptor inhibitors: two case reports]. An Bras Dermatol; 2009 Nov-Dec;84(6):667-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Reações cutâneas secundárias ao uso dos inibidores do receptor de fator de crescimento epidérmico: relato de dois casos.
  • EGFR inhibitors have shown efficacy in the treatment of neoplasms of the head, neck, colon and lung.
  • They are usually reversible, but when severe, limit the use of the drug.
  • An adequate dermatologic approach is necessary for an effective therapy against cancer.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antineoplastic Agents / adverse effects. Drug Eruptions / etiology. Protein Kinase Inhibitors / adverse effects. Quinazolines / adverse effects. Receptor, Epidermal Growth Factor / antagonists & inhibitors

  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20191181.001).
  • [ISSN] 1806-4841
  • [Journal-full-title] Anais brasileiros de dermatologia
  • [ISO-abbreviation] An Bras Dermatol
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab
  •  go-up   go-down






Advertisement